Thanks KK2 - If apabetalone is able to perform in BETonMACE in this patient group the way it did in the post hock analysis then we should be able to crush Repatha from a price point and an expanded potential patient group that would include reducing the odds of a stroke. The BoM patient group, diabetic, low HDL and high CRP is the best responding group in our previous Phase II trials. From previous presentations it seems to me that using $5,000 per year cost for apabetalone would be about one tenth the cost of Repata.

When reading this article and seeing that they went two and a half years on Repatha it made me wonder if that also had something to do with the extended date of completion for BETonMACE.

tada